Intravenous Iron Drugs Market New Development and Future Expansion to 2033
Global Intravenous Iron Drugs Market was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 6.3 Bn by 2032, finds Fact.MR in a recent market survey. As per the findings of the report, Intravenous Iron Drugs revenue through Ferric Carboxymaltose will garner significant demand in the market as the bulk of revenue will be generated through them.
The American Heart Association predicts that by 2035, more
than 130 million adults in the United States will have cardiovascular disease.
In addition, the Centers for Disease Control and Prevention reports that 0.6
million Americans die each year from heart disease. This information leads
directly to the number of hospital admissions.
The Ferric Carboxymaltose (FCM) segment led the market for
intravenous iron medicines in 2021, with nearly 50% revenue share due to its
expanding use, improved performance, and lower cost. It is a parenteral iron
medication devoid of dextran which is suggested for the quick and high-dose
replacement of depleted iron reserves. This medicine is a stable compound with
the benefit of not containing any extraneous ingredients and having a very low
immunogenic potential; hence, it poses a very low risk of anaphylactic
responses. FCM has a higher effectiveness in terms of boosting hemoglobin
levels and has fewer side effects. The tremendous rise may also be attributed
to the FDA approval of Injectates in North America as well as its approval
outside of North America.
The region's expanding senior population is a primary
driver of industry development. According to US Census Bureau forecasts, the
number of Americans aged 65 and older would rise from 52 million in 2018 to
roughly 95 million by 2060. Furthermore, the overall percentage of people aged
65 and older is projected to increase from 16% to 23%.
It may be linked to the presence of a higher incidence of
cancer, intestinal illnesses, and renal disease in the specific area. These
conditions also are reinforcing its dominance. It has also contributed to the
growth of women's health awareness and the awareness about celiac disease.
Competitive Landscape
Some of the key players in the global Intravenous Iron
Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals;
Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield
Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG
Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S;
and Shield Therapeutics Plc among others.
Read
More@ https://www.futuremarketinsights.com/reports/intravenous-iron-drugs-market
Market
Segments Covered in Intravenous Iron Drugs Industry Analysis
By
Product Type:
- Iron
Dextran
- Iron
Sucrose
- Ferric
Carboxymaltose
- Other
Product Types
By
Indication:
- Chronic
Kidney Disease
- Inflammatory
Bowel Disease
- Cancer
- Other
Applications
Comments
Post a Comment